Domov › Crohnova bolezen › Connecticut
Klinične študije za Crohnova bolezen v Connecticut
14 študij za Crohnova bolezen išče udeležence na lokacijah v Connecticut.
Mesta v Connecticut
Uradno besedilo študije (angleško)
Extension Study of Long-term Safety and Efficacy of Tulisokibart in Participants With Crohn's Disease or Ulcerative Colitis (MK-7240-011)
- Connecticut Clinical Research Institute ( Site 0297), Bristol
Vključevanje udeležencevFaza 3
Vse starosti · Vsi spoli · Posodobljeno 2. okt. 2026 · NCT06651281A Study to Evaluate the Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderate to Severe Crohn's Disease (MK-7240-008)
- Yale University School of Medicine-Digestive Disease ( Site 5019), New Haven
Vključevanje udeležencevFaza 3
Starost 16–80 · Vsi spoli · Posodobljeno 2. okt. 2026 · NCT06430801Study of Targeted Therapies for the Treatment of Adult Participants With Moderate to Severe Crohn's Disease
- Danbury Hospital, Western Connecticut Health Network /ID# 265556, Danbury
- Yale University School of Medicine /ID# 266786, New Haven
Vključevanje udeležencevFaza 2
Starost 18–75 · Vsi spoli · Posodobljeno 25. sep. 2026 · NCT06548542A Study of Guselkumab Versus Risankizumab in Participants With Moderately to Severely Active Crohn's Disease
- Medical Research Center of Connecticut, Hamden
Vključevanje udeležencevFaza 3
Starost 18 in več · Vsi spoli · Posodobljeno 25. sep. 2026 · NCT07499232Testing an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVO
- Smilow Cancer Center/Yale-New Haven Hospital, New Haven
- Yale University, New Haven
Vključevanje udeležencevFaza 1
Starost 18 in več · Vsi spoli · Posodobljeno 23. sep. 2026 · NCT03816345An Induction Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Crohn's Disease
- Yale University Digestive Disease-Site Number: 8400108, New Haven
Vključevanje udeležencevFaza 3
Starost 16–80 · Vsi spoli · Posodobljeno 23. sep. 2026 · NCT07184931A Master Protocol (AMAZ): A Study of Mirikizumab (LY3074828) in Pediatric Participants With Ulcerative Colitis or Crohn's Disease (SHINE-ON)
- Connecticut Children's Medical Center, Hartford
Vključevanje udeležencevFaza 3
Starost 2–19 · Vsi spoli · Posodobljeno 22. sep. 2026 · NCT04844606A Study of Vedolizumab Intravenous (IV) and Adalimumab or Vedolizumab and Ustekinumab in Adults With Crohn's Disease
- Medical Research Center of Connecticut, LLC, Hamden
Vključevanje udeležencevFaza 4
Starost 18–70 · Vsi spoli · Posodobljeno 9. sep. 2026 · NCT06045754A Study of Mirikizumab (LY3074828) in Pediatric Participants With Crohn's Disease
- Connecticut Children's Medical Center, Hartford
Vključevanje udeležencevFaza 3
Starost 2–17 · Vsi spoli · Posodobljeno 24. avg. 2026 · NCT05509777Treat-to-Target of Endoscopic Remission in Patients With IBD in Symptomatic Remission
- Yale University, New Haven
Vključevanje udeležencev
Starost 18 in več · Vsi spoli · Posodobljeno 7. avg. 2026 · NCT05230173Zymfentra (Infliximab-dyyb) REal World Cohort STudy
- Yale University School of Medicine, New Haven
Vključevanje udeležencevOpazovalna študija
Starost 18 in več · Vsi spoli · Posodobljeno 5. avg. 2026 · NCT07237516Assessment and Educational Intervention to Reduce Ultra-processed Food Consumption in Pediatric Patients With IBD
- Connecticut Children's Medical Center, Hartford
Vključevanje udeležencevOpazovalna študijaVabljeni zdravi prostovoljci
Starost 10–21 · Vsi spoli · Posodobljeno 16. jul. 2026 · NCT07224113Crohn's Disease: Efficacy, Safety, and Pharmacokinetics of Upadacitinib in Pediatric Subjects With Moderately to Severely Active Crohn's Disease
- Connecticut Children's Medical Center - Hartford /ID# 262256, Hartford
Vključevanje udeležencevFaza 3
Starost 2–17 · Vsi spoli · Posodobljeno 24. jun. 2026 · NCT06332534Clinical, Imaging, and Endoscopic Outcomes of Children Newly Diagnosed With Crohn's Disease
- Connecticut Children's Medical Center, Hartford
Vključevanje udeležencevFaza 4
Starost 6–17 · Vsi spoli · Posodobljeno 27. maj 2026 · NCT05781152Vir: ClinicalTrials.gov, podatki pridobljeni 5. okt. 2026. Vsaka študija ima svoje pogoje vključitve; ekipa študije odloči, kdo lahko sodeluje.